NONPROFIT, NONPARTISAN PLATFORM OF ACCURATE SCIENCE-BASED SOLUTIONS TO COVID-19

Company Report: Sonnet Biotherapeutics

Sonnet Biotherapeutics is a publicly traded company listed on NASDAQ (SONN:NASDAQ) that has developed a unique, new and timely platform for the delivery of an enormous number of biologic drug applications for nearly any indication. Their Fully Human Albumin Binding (FHAB) platform technology leverages a single chain antibody fragment (scFV) coupled with two flexible linker peptides that are capable of attaching to nearly any type of biologic or small molecule therapeutic. Engineered into the scFV is an albumin binding domain that allows the FHAB to directly interact with endogenous albumin, thereby exploiting its biodistribution properties to lymphoid tissues and tumor micro-environments. The technology has applications in oncology and for Covid – 19.